NEXT SCIENCE®

ASX ANNOUNCEMENT / MEDIA RELEASE

18 April 2024

Publication of study showing infection prevention benefit from XPERIENCE™ when used in Primary Joint Arthroplasty procedures

Next Science Limited (ASX:NXS) ("Next Science" or "the Company") today announces the publication of a study which found XPERIENCETM to be efficacious in preventing periprosthetic joint infection (PJI) in patients undergoing primary knee, hip and shoulder arthroplasties (joint replacement).

Next Science is a medical technology company focused on commercialising its proprietary XBIO™ suite of products to reduce the impact of biofilm-based infections in human health.

On 3 November 2023, Next Science announced that Dr Robert Harris MD had released the findings of a retrospective study on VuMedi¹ which found Next Science's advanced surgical irrigation product, XPERIENCE™ to be efficacious in preventing PJI in Joint Arthroplasty (JA) and warranted further investigation as the "sole antimicrobial irrigant in prospective, randomised, controlled clinical trials".²

The study findings have now undergone a peer review process and been published in the *Journal of Orthopaedic Surgery*.

The article entitled "Efficacy of a Novel Intraoperative Surgical Irrigant in Preventing Periprosthetic Joint Infections in Primary Knee, Hip and Shoulder Arthroplasties: A Retrospective Analysis" by Robert Harris MD and Marshall Williams MD can be accessed via the link below:

https://onlinelibrary.wiley.com/doi/10.1111/os.14052

Next Science's CEO and Managing Director I.V. Hall said: "The retrospective study by leading orthopaedic surgeon Dr Robert Harris showed a zero percent infection rate in a cohort of 423 patients up to 90 days post-surgery. The publication of these findings in the *Journal of Orthopaedic Surgery* means the study will now receive broader recognition in the Orthopaedic community and adds to the growing body of clinical evidence that will support Next Science being able to challenge for standard of care in surgical irrigation. We will continue to work closely with surgeons to conduct clinical research that demonstrates the effectiveness of Next Science's products."

Approved and authorised for release by the Managing Director.

¹ VuMedi is a video education platform for doctors.

² Refer to ASX announcement on 3 November 2023.



Media & Investor Enquiries

Françoise Dixon

Phone: +61 412 292 977

Email: fdixon@nextscience.com

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the company's primary focus is on the development and continued commercialisation of its proprietary XBIO™ technology to reduce the impact of biofilm-based infections in human health. XBIO™ is a unique, non-toxic technology with proven efficacy in eradicating both biofilm-based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its XBIO™ technology. For further information visit: www.nextscience.com

Forward looking statements

This announcement may contain forward looking statements which may be identified by words such as "believes", "considers", "could", "estimates", "expects", "intends", "may" and other similar worlds that involve risks and uncertainties. Such statements are not guarantees of future performance and involved known and unknown risks uncertainties, assumptions and other important factors, many of which are beyond the control of Next Science or its Directors and management and could cause Next Science's actual results and circumstances to differ materially from the results and circumstances expressed or anticipated in these statements. The Directors cannot and do not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this announcement will actually occur and investors are cautioned not to place undue reliance on these forward-looking statements.